Dear John,

Join us for a free live taping of A Health Podyssey on October 22 where Jennifer Kao will discuss her upcoming paper exploring the impact of risk evaluation and mitigation strategies on generic approvals of US pharmaceutical products.

Today's Featured Articles

Criminalized For Surviving: Parenthood Under Surveillance

Meghann Perry

You Found Your Home There

Cari Ann Fisher

How Tariffs Could Disrupt Health Care—And What States Can Do About It

Geeta Minocha

part of our Health Policy At A Crossroads series

Medicaid’s New Address Verification Requirements Could Impose Significant Burdens

Marcella Maguire and Alison Barkoff

part of our Health Policy At A Crossroads series

More on Tariffs

Tariffs: Added Strain On The US Health Care System

Ahmad M. Hider et al. (September 2025)

Trump’s Ongoing Tariff Chaos Will Make Medications Less Affordable And Harder To Find

Aaron S. Kesselheim and Jerry Avorn (July 2025)

Pharmaceutical Tariffs: Potential Impacts And The Need For Vulnerability Assessments

Thomas Roades et al. (March 2025)

Medicaid’s Role in Rising Buprenorphine Use w/ Stephen Crystal

Health Affairs' Rob Lott interviews Stephen Crystal of Rutgers University about his recent paper exploring how states with substantial increases in buprenorphine uptake as an opioid use disorder treatment response grew alongside increased Medicaid prescribing from 2018–24.

Prior Authorization: Current State and Potential Reform

On September 29 we hosted an exclusive Insider virtual event exploring prior authorization.

Health Affairs collected a panel of experts to discuss the current state of prior authorization and how prior authorization processes and regulations affect drugs/pharmaceuticals, oncology/cancer care, and opioid use disorder treatment plans.

Speakers included A. Mark Fendrick, Ravi Gupta, Michael Anne Kyle, and Christina Andrews.

Become an Insider today to watch this event.